Homologous recombination deficiency in Ovarian Cancer: The Game-Changer for First-Line Maintenance Therapy - PubMed
6 hours ago
- #PARP inhibitors
- #HRD
- #Ovarian Cancer
- Homologous recombination deficiency (HRD) is crucial in epithelial ovarian cancer (EOC), especially high-grade serous subtypes.
- HRD makes tumor cells sensitive to platinum-based chemotherapy and PARP inhibitors due to impaired DNA repair.
- Genomic assays like Myriad myChoice® CDx and FoundationFocus™ CDx BRCA LOH identify HRD status through genomic instability patterns.
- Emerging diagnostic methods include circulating tumor DNA-based techniques and AI-driven computational pathology.
- Challenges include tumor heterogeneity, static genomic scar assays, and resistance via reversion mutations.
- Functional assays and integrative strategies offer dynamic insights into DNA repair capacity for better patient selection.
- HRD testing at diagnosis is cost-effective, optimizing PARP inhibitor use and healthcare resource allocation.
- The review covers HRD's biological rationale, diagnostics, therapeutic impact, and economic aspects in EOC.